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Letters to the Editor 103Double-carbapenem regimen, alone or in
combination with colistin, in the treatment
of infections caused by carbapenem-
resistant Klebsiella pneumoniae (CR-Kp)Dear Editor,
We read with interest the article published by Zhang
et al., concerning the emergence of infection caused by a
hypervirulent (hv) carbapenem-resistant Klebsiella pneu-
moniae (CR-Kp) strain.1
Infections caused by CR-Kp represent an emerging threat
worldwide due to high mortality rate and limited thera-
peutic options.2 Although considered as part of antimicro-
bial combinations against CR-Kp, colistin use might be
limited by its potential nephrotoxicity and resistance;
thus, colistin-free unconventional approaches such as the
double-carbapenem (DC) regimen have recently been
proposed.3e6
In the present study, we evaluated the clinical effec-
tiveness and the in-vitro activity of the DC regimen [ertape-
nem (ERT) plus high dose of meropenem (MEM)], alone or in
combination with colistin (COL), in the treatment of infec-
tions caused by CR-Kp.
Over a 3-years period (2012e2015), we enrolled all
consecutive patients with CR-Kp infection treated with
the DC regimen, with or without colistin, at the Department
of Public Health and Infectious Diseases of “Sapienza”
University (Rome) and at the Mediterranean Neurological
Institute “Neuromed” (Pozzilli).
The use of these combinations was decided by the
attending Infectious Diseases Specialist according to pa-
tients’ clinical condition, renal function and strains sus-
ceptibility pattern. Early response was defined as
resolution of signs and symptoms of infection at 5th day
of antimicrobial treatment whereas the overall follow-up
was set up at 60-days. Patients gave informed written
consent.
Clinical samples underwent microbiological procedures
as for daily practice. Additional in-vitro studies included
phenotypic determination of carbapenemases7 and evalua-
tion of MEM þ ERT and COL þ MEM þ ERT synergism
throughout killing studies. In the triple combination,
we decided to lower MEM rather than COL or ERT concen-
trations because in the presence of high MEM MICs, which
were far above the achievable concentration of the drug,
there was a higher probability of reaching serum MEM con-
centration with 0.5 MIC and 0.25 MIC concentrations
than with 1 MIC. The area under the curve (AUC)
of each combination, expressed as mean  SD, was
calculated. The number of CFU/mL was expressed as
mean  standard error of the mean (SEM). For statistical
analyses we used GraphPad Prism version 5 (Graphpad Soft-
ware MacKiev).
A total of 32 patients with CR-Kp infection were enrolled
in the study: subjects receiving ERT þ MEM (Group A;
nZ 18) and subjects receiving COL þ MEM þ ERT (Group B;
n Z 14). Clinical characteristics of study population are
shown in Table 1.Overall, clinical success was achieved in 75% of subjects.
The triple combination therapy was used more frequently
in patients with a more severe condition at the time of
infection (i.e. septic shock). Although patients in Group B
tended to have an earlier clinical response than those in
Group A, no statistical difference was found between the 2
groups regarding early response to therapy and mortality at
60-days.
Killing studies were performed on 28 CR-Kp strains (16
from Group A, 12 from Group B) whereas the remaining 4
strains were not available. MICs50/90 of both MEM and ERT
were 128 and 256 mg/mL by macrobroth dilution. All the
strains were KPC producers. Results of killing studies are
shown in Fig. 1.
In the DC group (n Z 16 strains, Fig. 1a), bactericidal
activity of ERT þ MEM was observed in 12/16 (75%) at 8 h
and raised to 14/16 (87.5%) at 24 h whereas in the
COL þ DC group (n Z 12 strains, Fig. 1b), the triple com-
bination (COL1 MIC þ MEM1 MIC þ ERT1 MIC) showed a
more rapid bactericidal activity than the double-
carbapenem regimen at MEM1 MIC þ ERT1 MIC (8/12
versus 6/12 at 8 h) and this effect was confirmed
even when sub-inhibitory concentrations of drugs were
tested. Furthermore, the triple combination at all the
tested concentrations was bactericidal at 24 h. Interest-
ingly, the bactericidal effect of the combination
COL þ MEM þ ERT was confirmed even in the presence of
COL MIC 2 mg/mL.
In the present study, we enrolled patients treated with
two types of unconventional regimens (MEM þ ERT in 18
patients and COL þ MEM þ ERT in 14 subjects).
In the in-vitro analyses, we showed that the addition of
COL to the DC regimen obtained a rapid bactericidal activ-
ity, which was maintained up to 24 h. Of note, the activity
of this combination was observed even at sub-inhibitory
concentrations of the drugs, with no statistically significant
differences in the AUCs of the tested concentrations.
Based on our results, the addition of colistin to
MEM þ ERT might be useful by inducing an earlier
antibacterial activity than that obtained with the
double-carbapenem regimen alone. This effect might be
crucial in the setting of more severe infections, where a
rapid antibacterial effect of an antimicrobial regimen is
auspicable in order to improve the clinical outcome of the
patients, even when the presence of colistin resistance
might discourage its use. Our results could lead to the
hypothesis that starting with an aggressive treatment of
colistin þ ertapenem þ meropenem followed by a
therapeutic switch to a less toxic regimen (i.e. the
double-carbapenem regimen) might be a reasonable
therapeutic options against systemic infections caused
by CR-Kp.8
Furthermore, our experiments showed that even in the
presence of higher COL MICs (2 mg/mL) the combination of
COL þ MEM þ ERTwas highly effective. In particular, all the
patients with COL resistance (n Z 3) had clinical improve-
ment at 60-days of follow-up. In these cases, the
detergent-like property of colistin might have a crucial
role in facilitating the penetration of the other drugs into
the bacteria.9
One of the major features of the present study is the
presence of both clinical and in-vitro results. In an era in
Table 1 General characteristics of study population.
Study population
(n Z 32)
DC groupa
(n Z 18, Group A)
COLb þ DC group
(n Z 14, Group B)
p-value
Demographic characteristics
 Age (years), M  SD 55.1  15.2 55.6  13.6 54.4  17.5 0.74
 Sex (M:F) 23:9 14:4 9:5 0.45
 APACHE III score, M  SD 64.9  29.6 50.7  28.1 83.2  20.3 0.001
 2 Comorbidities 14 (43.7) 5 (27.7) 9 (64.2) 0.07
Classification of infection, n (%)
 CA:HCA:HA 0:6:26 0:6:12 0:0:14 0.0001
 Length of hospitalization before infection, daysc 17.5 (2e437) 14 (2e65) 23 (5e437) 0.005
Risk factors for infection (previous 12 months), n (%)
 Previous hospitalization 22 (68.7) 15 (83.3) 7 (50) 0.02
 Intensive care unit 22 (68.7) 10 (55.5) 12 (85.7) 0.06
 Vescical catheter 18 (56.2) 12 (66.6) 6 (42.8) 0.12
 Central venous catheter (CVC) 11 (34.3) 9 (50) 2 (14.2) 0.28
Risk factors for infection (previous 72 h), n (%)
 Naso-gastric tube 18 (56.2) 6 (33.3) 12 (85.7) 0.004
 Fibrobroncoscopy 14 (43.7) 4 (22.2) 10 (71.4) 0.01
 Parenteral total nutrition 14 (43.7) 4 (22.2) 10 (71.4) 0.01
 CVC 20 (62.5) 7 (38.8) 13 (92.8) 0.002
Previous antibiotic therapy (90 days), n (%) 29 (90.6) 15 (83.3) 14 (100) 0.23
 Cephalosporin 10 (31.2) 3 (16.6) 7 (50) 0.06
 Penicillins 18 (56.2) 7 (38.8) 11 (78.5) 0.03
 Carbapenems 15 (46.8) 6 (33.3) 9 (64.2) 0.45
 Beta-lactams (overall) 27 (84.3) 13 (72.2) 14 (100) 0.05
 Fluoroquinolones 10 (31.2) 5 (27.7) 5 (35.7) 0.71
 Colistin 9 (28.1) 4 (22.2) 5 (35.7) 0.45
CR-Kp rectal colonization, n (%) 27 (96.4) 13/14 (92)e 14/14 (100) 0.37
Colistin-resistance, n (%) 11 (34.3) 8 (44.4) 3 (21.4) 0.26
Clinical presentationd, n (%)
 Sepsis 5 (15.6) 3 (16.6) 2 (14.2) 0.99
 Severe sepsis 13 (40.6) 7 (38.8) 6 (42.8) 0.99
 Septic shock 8 (25) 2 (11.1) 6 (42.8) 0.09
 Type of infection
Pneumonia 9 (28.1) 4 (22.2) 5 (35.7) 0.99
EV infection 3 (9.3) 2 (11.1) 1 (7.1) 0.87
UT infection 9 (28.1) 8 (44.4) 1 (7.1) 0.04
CVC infection 6 (18.7) 0 (0) 6 (42.8) 0.003
Primary bacteremia 6 (18.7) 4 (22.2) 2 (14.2) 0.67
 Presence of bacteremic infection 18 (56.2) 8 (44.4) 10 (71.4) 0.16
Definitive therapy, n (%)
 Early responsee 23 (71.8) 11 (61.1) 12 (85.7) 0.23
 Length of definitive therapy, daysc 21 (7e150) 18.5 (7e150) 25 (7e34) 0.04
 Clinical response (days)c 4 (2e15) 4 (2e15) 4 (3e12) 0.68
 Microbiological response (days)f c 4 (2e17) 3 (2e17) 5 (3e10) 0.43
 Adverse events, n (%)g 6 (18.7) 3 (16.6) 3 (21.4) 1.00
Outcome at 60 days, n (%)
 Exitus 6 (18.7) 3 (16.6) 3 (21.4) 0.99
 Relapseh 2 (6.2) 2 (11.1) 0 (0) 0.49
 Improvement 24 (75) 13 (72.2) 11 (78.5) 0.89
DC: double-carbapenem; COL: colistin; CR-Kp: carbapenem-resistant Klebsiella pneumoniae; CA: community-acquired; HCA: health-
care associated; HA: hospital-acquired; EV: endo vascular; UT: urinary tract; CVC: central venous catheter.
a The DC regimen consisted of ERT 1 g (1-h infusion) followed by high dose of MEM (2 g every 8 h, 3-h infusion).
b COL administration was 9,000,000 UI as a loading dose followed (after 12 h) by 4,500,000 UI every 12 h.
c Data are expressed as median (range).
d Clinical presentation (sepsis, severe sepsis and septic shock) was determined according to period guidelines.10.
e Early clinical response was defined as resolution of signs and symptoms of infections (i.e. defervescence, improvement of clinical
conditions, reduction of white blood cells, C-reactive protein) achieved at 5th day of antimicrobial treatment.
f Microbiological response was defined as negativity of cultures performed after 5 days of antimicrobial treatment.
g Type of adverse events included: mild sodium-disorder (n Z 1, Group A), vomiting (n Z 1, Group A), seizures (n Z 2, 1 Group A, 1
Group B), leukopenia (n Z 2, Group B).
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Figure 1 Bactericidal activity and killing studies of double-carbapenem regimen (a) and colistin (COL) plus double-carbapenem
regimen (b). DC: double-carbapenem; MEM: meropenem; ERT: ertapenem; GC: growth control; AUC: area under the curve; SD:
standard deviation. Dashed line represents bactericidal activity. a: bactericidal activity was defined as 3-log10 CFU/ml reduction
of the initial bacterial count at each time point; b: synergistic activity was defined as a 100-fold decrease in CFU/mL between the
combination and its most active constituent at the same concentration after 24 h.
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seem to be no longer informative, we believe that per-
forming in-vitro synergy studies could represent an addi-
tional tool in order to guide treatment decisions andpredict the potential clinical efficacy of the chosen
combination.
In conclusion, we were able to demonstrate that both
the double-carbapenem alone and the double-carbapenem
106 Letters to the Editorregimen plus colistin were clinically and microbiologically
effective in the treatment of infections caused by CR-Kp,
the latter even at sub-inhibitory concentrations.
MEM þ ERT might be a valid therapeutic option when COL
use is discouraged whereas COL þ MEM þ ERT might be
considered in subjects presenting with more severe condi-
tions (i.e. septic shock), where an early clinical response is
auspicable.
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